Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 5/20 | 0.66 |
| ▸ | THRB | P10828 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | PKM | P14618 | 7/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20703688 | 0.94 | ALDH1A1 (0.60) | TP53THRBMAPTPKMLMNA | |
| SCHEMBL18184455 | 0.87 | TP53 (0.67) | TP53THRBMAPTPKMLMNA | |
| SCHEMBL24809087 | 0.84 | TP53 (0.64) | TP53THRBMAPTPKMLMNA | |
| SCHEMBL18184511 | 0.84 | TP53 (0.64) | TP53THRBMAPTPKMLMNA | |
| SCHEMBL15202464 | 0.84 | PKM (0.58) | TP53THRBMAPTPKMMEN1 | |
| SCHEMBL20364522 | 0.83 | TP53 (0.63) | TP53THRBMAPTPKMLMNA | |
| SCHEMBL25010388 | 0.82 | TP53 (0.71) | TP53THRBMAPTPKMLMNA | |
| SCHEMBL15202423 | 0.82 | MAPT (0.49) | TP53THRBMAPTPKMLMNA | |
| SCHEMBL2953764 | 0.81 | MMP12 (0.64) | TP53THRBMAPTPKMLMNA | |
| SCHEMBL25010395 | 0.78 | TP53 (1.00) | TP53THRBPKMLMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11078358-B2 | Curable composition including epoxy resin and curable solid filler | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2021-08-03 | — | — | US | disclosed |
| EP-3661990-A1 | CURABLE COMPOSITION INCLUDING EPOXY RESIN AND CURABLE SOLID FILLER | 3M Innovative Properties Company (US) | 2020-06-10 | — | — | EP | disclosed |
| US-20200148878-A1 | CURABLE COMPOSITION INCLUDING EPOXY RESIN AND CURABLE SOLID FILLER | 3M INNOVATIVE PROPERTIES COMPANY | 2020-05-14 | — | — | US | disclosed |
| CN-110997748-A | Curable composition comprising an epoxy resin and a curable solid filler | 3M创新有限公司 | 2020-04-10 | — | — | CN | disclosed |
| EP-2970215-B1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE DEUTSCHLAND (DE) | 2019-04-17 | — | — | EP | disclosed |
| WO-2019027746-A1 | CURABLE COMPOSITION INCLUDING EPOXY RESIN AND CURABLE SOLID FILLER | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2019-02-07 | — | — | WO | disclosed |
| US-9656955-B2 | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-9650334-B2 | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. (US) | 2017-05-16 | — | — | US | disclosed |
| EP-2970215-A1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014140310-A1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-18 | — | — | WO | disclosed |
| US-20140275086-A1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-18 | — | — | US | disclosed |
| US-20140275087-A1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275086-A1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | SLC6A7, GFPT1, SUGT1 | TP53 2562/4885THRB 2960/4885MAPT 613/4885 |
| US-20140275087-A1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | SLC6A7, GFPT1, SUGT1 | TP53 2562/4885THRB 2960/4885MAPT 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.